Stifel resumed coverage on Rhythm Pharmaceuticals with a new price target
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel resumed coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $78.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2025 | $63.00 | Neutral → Buy | BofA Securities |
| 3/5/2025 | $78.00 | Buy | Stifel |
| 1/2/2025 | $80.00 | Buy | Jefferies |
| 12/20/2024 | $76.00 | Outperform | Oppenheimer |
| 10/21/2024 | $70.00 | Buy | Guggenheim |
| 9/18/2024 | $64.00 | Buy | H.C. Wainwright |
| 9/17/2024 | $64.00 | Mkt Outperform | JMP Securities |
| 5/8/2024 | $49.00 → $42.00 | Buy → Neutral | BofA Securities |
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks -- -- -20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks -- -- Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025 -- -- Company to host conference call today at 8 a.m. ET -- BOSTON, April 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage bi
BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the Pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. Conference Call InformationRhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Monday, April 7, to discuss these clinical data. Parti
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it reacquired the rights to IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement with RareStone Group Ltd. "Rhythm continues to execute on our strategy of developing setmelanotide and the next generation of MC4R agonists with the goal of making these treatments available to patients from around the world who may benefit," David Meeker, MD, Chairman, CEO
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks -- -- -20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks -- -- Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025 -- -- Company to host conference call today at 8 a.m. ET -- BOSTON, April 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage bi
BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the Pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. Conference Call InformationRhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Monday, April 7, to discuss these clinical data. Parti
-- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 -- -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity -- -- FDA approved expanded label for IMCIVREE to include children as young as 2 years old -- -- Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Feb
SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
BofA Securities upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $63.00
Stifel resumed coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $78.00
Jefferies initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $80.00
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
S-8 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)